SAT-6-1 A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder

Blashko, Carl A.

doi:10.1016/0924-977x(95)90327-a

Cited by 16 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(3) the antidepressant efficacy of serotonergic compounds (O'Rourke et al 1989 ;Blashko, 1995 ;Lam et al 1995) ; and (4) the behavioural responses to tryptophan depletion before and after light therapy (Lam et al 1996 ;Neumeister et al b, 1998 and during the summer (Neumeister et al 1998 b).…”

Section: Introductionmentioning

confidence: 99%

Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls

et al. 2001

View full text Add to dashboard Cite

These data suggest reductions in the availability of striatal DAT binding sites in untreated symptomatic depressed SAD patients. It remains unclear whether these reductions represent a primary defect or an attempt to overcome a state of possible lowered dopamine availability in the synaptic cleft during a depressive episode of SAD. However, these findings provide evidence that brain dopaminergic systems may be involved in the pathophysiology of SAD.

show abstract

Section: Introductionmentioning

confidence: 99%

Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Abnormal behavioural responses, the most notable being ' activation-euphoria ' after application of m-CPP before, but not after, light therapy or during summer, are confined to SAD patients only and are not found in healthy controls (Joseph-Vanderpool et al 1993 ;Jacobsen et al 1994 ;Schwartz et al 1997). Serotonergic compounds have been found to be effective in the treatment of SAD O'Rourke et al 1989 ;Blashko, 1995 ;Lam et al 1995). The assessment of cellular serotonergic function showed inconsistent results.…”

Section: Introductionmentioning

confidence: 99%

Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer

et al. 1998

View full text Add to dashboard Cite

show abstract

“…In the treatment of pure dysthymia sertraline has been compared with imipramine (Thase et al, 1996), and placebo (Guel® and Wiseman, 1995;Thase et al, 1996). The ecacy of sertraline in seasonal aective disorder (Blashko, 1995), and premenstrual dysphoric disorder (Yonkers et al, 1996) has also been demonstrated in placebocontrolled trials. The long-term ecacy of sertraline has also been established in studies which compared the ability of sertraline and placebo to prevent relapse in the medium term and to reduce the risk of the recurrence of new episodes of depression in the long term (Montgomery et al, 1991).…”

Section: Introductionmentioning

confidence: 99%

A Double-Blind Comparison of Sertraline and Imipramine in Outpatients with Major Depression: Acute (8 Weeks) and Continuation (16 Weeks) Treatment

Fournier¹,

Lane

Chouinard³

et al. 1997

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

In a double-blind multicentre trial in patients with major depression, the ecacy and the tolerability of sertraline were compared to those of imipramine, during an 8-week acute treatment phase followed by a 16-week continuation treatment phase in treatment responders. A total of 104 patients who met DSM-III-R criteria for major depression, HAM-D 17-item518 and Raskin Depression score > Covi Anxiety score, were randomized to receive either sertraline or imipramine. The initial daily dosage of 50 mg of sertraline or imipramine was rapidly titrated upwards in increments of 50 mg/day at weekly intervals, tolerability permitting, to a maximum of 200 mg/day by the fourth week. Eighty-eight patients completed at least 3 weeks of treatment and were included in the ecacy evaluable population. Both treatment groups demonstrated similar improvements on depression and anxiety rating scales during acute treatment, however, sertraline demonstrated signi®cantly more improvement relative to imipramine on the HAM-D and Covi Anxiety scales after 1 week of treatment. Sertraline was more eective (HAM-D 17-item, CGI-S, SCL-56 Total score, SCL-56 Depression score, Covi Anxiety score) than imipramine in reducing depressive symptoms at the end of 24 weeks of treatment. There were signi®cant improvements in all rating scales at week 24 relative to week 8 in the sertraline group but not in the imipramine group. The SCL-56 Total score, SCL-56 Depression score, Raskin Depression score and Covi Anxiety score at week 24 relative to week 8 showed signi®cantly greater improvement in the sertraline group compared to the imipramine group. Imipramine was associated with a signi®cantly higher incidence of dry mouth, sweating, constipation, palpitations, and a signi®cantly higher heart rate and blood pressure. Sertraline was associated with a signi®cantly higher incidence of diarrhoea/loose stools and insomnia. This study demonstrated a faster onset of therapeutic eect for sertraline relative to imipramine, re¯ecting the initiation of sertraline in a therapeutic dose of 50 mg/day and the need for gradual titration of imipramine to a therapeutic dose, at the beginning of treatment. Although ecacy was similar in both treatment groups at the end of the 8 weeks of acute therapy, sertraline-treated patients continued to manifest gradual improvements in depressive and anxiety symptoms during the 16 weeks of continuation therapy such that sertraline-treated patients were signi®cantly more improved at the end of 24 weeks of therapy.

show abstract

SAT-6-1 A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder

Cited by 16 publications

References 0 publications

Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls

Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls

Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer

A Double-Blind Comparison of Sertraline and Imipramine in Outpatients with Major Depression: Acute (8 Weeks) and Continuation (16 Weeks) Treatment

Contact Info

Product

Resources

About